The Mediterranean diet, named after the traditional eating habits of Greece and Italy, was once again linked to multiple cardiovascular benefits. The focus of this latest meta-analysis was adults over the age of 60.

Landiolol, sold by AOP Health under the brand name Rapiblyk, is an intravenous treatment designed to start working right away.

PPM is still relatively common after TAVR, especially among patients with a small aortic annulus. What can be done to minimize the risk of PPM? Does valve type play a role? Researchers explored those questions, and many others.

Gilbert Tang, MD, surgical director of the structural heart program at the Mount Sinai Health System, discussed a key challenge care teams often encounter during tricuspid valve procedures. 

Abbott already has an FDA-approved self-expanding TAVR valve, the Navitor system, on the market. The company is now evaluating the safety and effectiveness of a new balloon-expandable device that could potentially be implanted using software guidance. 

The pressure changes associated with contrast injections are minimal, researchers noted, especially once you move away from the tip of the catheter. 

Charles E. Mullins, MD, a U.S. Army veteran who went on to practice medicine for five decades, died at the age of 92. SCAI shared a loving tribute to Mullins, calling him the "father of modern interventional pediatric cardiology."

Cardiothoracic surgeons at Emory University Hospital implanted the BrioVAD System, a new type of ventricular assist device from BrioHealth Solutions, for the very first time in the United States. The advanced technology, designed to minimize adverse events and improve quality of life, has been under development since 2008. 

The Sapien 3 Ultra Resilia TAVR valve from Edwards Lifesciences is associated with a significantly higher survival rate after one year than the company's previous balloon-expandable valves. Researchers identified other key benefits as well, sharing their findings in JACC: Cardiovascular Interventions.

Acoramidis, a selective transthyretin stabilizer being sold under the brand name Attruby, is now the second ATTR-CM medication to gain FDA approval.